@article{10.37349/etat.2024.00207,
abstract = {Monoclonal antibodies (mAbs) are an effective drug for targeted immunotherapy in several cancer types. However, so far, no antibody has been successfully developed for certain types of cancer, including T-cell acute lymphoblastic leukemia (T-ALL). T-ALL is an aggressive hematologic malignancy. T-ALL patients who are treated with chemotherapeutic drugs frequently relapse and become drug resistant. Therefore, antibody-based therapy is promising for T-ALL treatment. To successfully develop an antibody-based therapy for T-ALL, antibodies that induce death in malignant T cells but not in nonmalignant T cells are required to avoid the induction of secondary T-cell immunodeficiency. In this review, CD99 tumor associated antigen, which is highly expressed on malignant T cells and lowly expressed on nonmalignant T cells, is proposed to be a potential target for antibody therapy of T-ALL. Since certain clones of anti-CD99 mAbs induce apoptosis only in malignant T cells, these anti-CD99 mAbs might be a promising antibody drug for the treatment of T-ALL with high efficiency and low adverse effects. Moreover, over the past 25 years, many clones of anti-CD99 mAbs have been studied for their direct effects on T-ALL. These outcomes are gathered here.},
author = {Kotemul, Kamonporn and Kasinrerk, Watchara and Takheaw, Nuchjira},
doi = {10.37349/etat.2024.00207},
journal = {Exploration of Targeted Anti-tumor Therapy},
pages = {96--107},
title = {{CD99 tumor associated antigen is a potential target for antibody therapy of T-cell acute lymphoblastic leukemia}},
url = {https://www.explorationpub.com/Journals/etat/Article/1002207},
volume = {5},
year = {2024}，
number = {1}
}